T Wästerlid1,2, M Mohammadi3, K E Smedby1,2, I Glimelius1,4, M Jerkeman5, M Bottai3, S Eloranta1. 1. Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. 2. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. 3. Institute of Environmental Medicine, Division of Epidemiology, Karolinska Institutet, Stockholm, Sweden. 4. Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden. 5. Department of Oncology, Lund University Hospital, Lund, Sweden.
Abstract
BACKGROUND: Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. OBJECTIVE: To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. METHODS: We identified 3905 adult patients diagnosed with DLBCL 2007-2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. RESULTS: Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)PS >2 : 2.02, 95% CI: 1.63-2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38-0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI >1 : 1.54, 95% CI: 1.32-1.80), but not with lymphoma-specific death (HRCCI >1 : 1.05, 95% CI: 0.86-1.28). CONCLUSION: Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.
BACKGROUND: Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. OBJECTIVE: To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. METHODS: We identified 3905 adult patients diagnosed with DLBCL 2007-2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. RESULTS: Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)PS >2 : 2.02, 95% CI: 1.63-2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38-0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI >1 : 1.54, 95% CI: 1.32-1.80), but not with lymphoma-specific death (HRCCI >1 : 1.05, 95% CI: 0.86-1.28). CONCLUSION: Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.
Authors: Maximilian Mair; Christian Straka; Thomas Buratti; Martina Tauber; Manfred Mitterer; Dominic Fong Journal: Ann Hematol Date: 2020-03-05 Impact factor: 3.673
Authors: Toby A Eyre; William Wilson; Amy A Kirkwood; Julia Wolf; Catherine Hildyard; Hannah Plaschkes; John Griffith; Paul Fields; Arief Gunawan; Rebecca Oliver; Stephen Booth; Jaimal Kothari; Christopher P Fox; Nicolas Martinez-Calle; Andrew McMillan; Mark Bishton; Graham P Collins; Chris S R Hatton Journal: Blood Adv Date: 2021-04-27
Authors: Qianwei Liu; Therese Ml Andersson; Anna Jöud; Qing Shen; Maria Ec Schelin; Patrik Ke Magnusson; Karin E Smedby; Fang Fang Journal: Clin Epidemiol Date: 2019-12-02 Impact factor: 4.790
Authors: Tove Wästerlid; Kim Oren Gradel; Sandra Eloranta; Ingrid Glimelius; Tarec C El-Galaly; Henrik Frederiksen; Karin E Smedby Journal: Br J Haematol Date: 2020-11-24 Impact factor: 6.998
Authors: Matthew James Smith; Edmund Njeru Njagi; Aurelien Belot; Clémence Leyrat; Audrey Bonaventure; Sara Benitez Majano; Bernard Rachet; Miguel Angel Luque Fernandez Journal: BMJ Open Date: 2021-11-30 Impact factor: 2.692
Authors: Willem Daneels; Michael Rosskamp; Gilles Macq; Estabraq Ismael Saadoon; Anke De Geyndt; Fritz Offner; Hélène A Poirel Journal: Front Oncol Date: 2022-02-28 Impact factor: 6.244
Authors: Maxine Je Lamb; Alexandra Smith; Daniel Painter; Eleanor Kane; Timothy Bagguley; Robert Newton; Debra Howell; Gordon Cook; Ruth de Tute; Andrew Rawstron; Russell Patmore; Eve Roman Journal: BMJ Open Date: 2021-02-22 Impact factor: 2.692